dazukibart (PF-06823859) / Pfizer  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dazukibart (PF-06823859) / Pfizer
NCT03181893 / 2020-004228-41: A Study In Adults With Moderate To Severe Dermatomyositis

Completed
2
75
Europe, US
PF-06823859 low, Placebo Arm, PF-06823859 high
Pfizer
Dermatomyositis
05/22
11/22
NCT05192200 / 2021-004787-10: An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

Completed
2
24
Europe, US
Anti-Beta Interferon (PF-06823859)
Pfizer
Dermatomyositis
11/23
11/23
NCT05879718: A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

Recruiting
2
48
Europe, Canada, US, RoW
Placebo, PF-06823859
Pfizer
Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous
12/25
11/26

Download Options